Diana Campelo Delgado,  —

Imara has opened applications for its second-annual “Real Impact” grants for community-based nonprofit organizations that support people with rare blood disorders, such as sickle cell disease (SCD) and beta-thalassemia. Through this year’s initiative, the biopharmaceutical company is awarding up to $150,000 to U.S. organizations that seek to address…

Imara is opening higher dose arms in two Phase 2b trials assessing the safety and efficacy of IMR-687, its potential therapy for sickle cell disease (SCD) and beta-thalassemia, in patients with these inherited blood disorders, the company announced. The decision, which applies to the Ardent (NCT04474314) and…

Global Blood Therapeutics (GBT) has opened its grant program — the Access to Excellent Care for Sickle Cell Patients (ACCEL), now in its third year — to proposals supporting programs aiming to improve access to high-quality healthcare for people with sickle cell disease (SCD). GBT will donate up…

Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to develop sickle cell disease (SCD) treatments using the CRISPR/Cas9 genome editing technology, the company announced. The approach, to be refined within living organisms (in vivo studies), aims to deliver a functional copy of…

The European Medicines Agency (EMA) has granted the designation of orphan drug to ARU-1801, an experimental gene therapy being developed by Aruvant, for the treatment of sickle cell disease (SCD). The decision, based on a positive recommendation by the EMA’s Committee for Medicinal Products for Human Use,…